Efficacy of Dupilumab for Atopic Dermatitis According to Clinical Course and Clinical Findings: A Multicentre Retrospective Study
DOI:
https://doi.org/10.2340/actadv.v101.369Keywords:
atopic dermatitis, dupilumab, eczema area and severity index, itch numerical rating scale, patient-oriented eczema measureAbstract
Abstract is missing (Short communication)
Downloads
References
Chello C, Carnicelli G, Sernicola A, Gagliostro N, Paolino G, Di Fraia M, et al. Atopic dermatitis in the elderly Caucasian population: diagnostic clinical criteria and review of the literature. Int J Dermatol 2020; 59: 716-721.
https://doi.org/10.1111/ijd.14891 DOI: https://doi.org/10.1111/ijd.14891
Silvestre Salvador F, Romero-Pérez D, Encabo-Durán B. Atopic dermatitis in adults: a diagnostic challenge. J Investig Allergol Clin Immunol 2017; 27: 78-88.
https://doi.org/10.18176/jiaci.0138 DOI: https://doi.org/10.18176/jiaci.0138
Hello M, Aubert H, Bernier C, Néel A, Barbarot S. Atopic dermatitis of the adult. Rev Med Interne 2016; 37: 91-99.
https://doi.org/10.1016/j.revmed.2015.10.345 DOI: https://doi.org/10.1016/j.revmed.2015.10.345
Czarnowicki T, He H, Krueger JG, Guttman-Yassky E. Atopic dermatitis endotypes an implications for targeted therapeutics. J Allergy Clin Immunol 2019; 143: 1-11.
https://doi.org/10.1016/j.jaci.2018.10.032 DOI: https://doi.org/10.1016/j.jaci.2018.10.032
Tamagawa-Mineoka R, Katoh N. Atopic dermatitis: identification and management of complicating factors. Int J Mol Sci 2020; 21: 2671.
https://doi.org/10.3390/ijms21082671 DOI: https://doi.org/10.3390/ijms21082671
Thomas KS, Apfelbacher CA, Chalmers JR, Simpson E, Spuls PI, Gerbens LAA, et al. Recommended core outcome instruments for health-related quality of life, long-term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting. Br J Dermatol 2021; 185: 139-146.
https://doi.org/10.1111/bjd.19751 DOI: https://doi.org/10.1111/bjd.19751
Chalmers JR, Simpson E, Apfelbacher CJ, Thomas KS, von Kobyletzki L, Schmitt J, et al. Report from the fourth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative). Br J Dermatol 2016; 175: 69-79.
https://doi.org/10.1111/bjd.14773 DOI: https://doi.org/10.1111/bjd.14773
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2021 Takeshi Nakahara, Makiko Kido-Nakahara, Daisuke Onozuka, Sawako Sakai, Tomoko Hirose, Nobutoshi Take , Akiko Sugiyama, Kayo Harada, Gaku Tsuji, Satoko Kikuchi, Futoshi Kohda
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
